When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ESALF - Lilly's New Donanemab Data For Alzheimer's
Eisai Co Ltd
2023-05-03 22:35:00 ET
Summary
Eli Lilly made headlines this morning with an announcement that their anti-amyloid antibody donanemab hit its endpoints in a Phase III clinical trial.
The natural comparison is with lecanemab (Leqembi), the recently approved antibody from Eisai and Biogen.
Lilly’s donanemab trial had a primary endpoint of change in that baseline decline after 18 months on their iADRS, but their antibody is dosed differently.